Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CNR2 | P34972 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385060 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL10665988 | 0.92 | CNR1 (0.85) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL15126343 | 0.90 | CNR1 (0.81) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL10460131 | 0.89 | CNR1 (0.80) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9690612 | 0.87 | CNR1 (0.77) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL9691060 | 0.86 | CNR1 (0.75) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| Pravadoline SCHEMBL488940 | 0.85 | CNR1 (1.00) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| Pravadoline SCHEMBL30353006 | 0.85 | CNR1 (1.00) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL17038792 | 0.85 | CNR1 (0.75) | CNR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL17035910 | 0.85 | CNR1 (0.75) | CNR1ALDH1A1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| EP-1773308-A1 | COMBINATION OF BUPROPION AND A SECOND COMPOUND FOR AFFECTING WEIGHT LOSS | Orexigen Therapeutics, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| US-20060100205-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-05-11 | — | — | US | claimed |
| WO-2006017504-A1 | COMBINATION OF BUPROPION AND A SECOND COMPOUND FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| WO-2005107806-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| EP-2943564-B1 | SL327 FOR USE IN SKIN REGENERATION | INT STEM CELL CORPORATION (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230404990-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CLEVELAND CLINIC FOUND (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20060100205-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-05-11 | — | — | US | disclosed |
| US-20060058293-A1 | Combination of bupropion and a second compound for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-03-16 | — | — | US | disclosed |
| WO-2005107806-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20040254208-A1 | Using mixture of opioid receptor antagonist and melanocortin antagonist; suppression appetites | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2004-12-16 | — | — | US | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100205-A1 | Compositions for affecting weight loss | OPRL1, CNR2, OPRK1 | CNR1 4/4885ALDH1A1 3537/4885TP53 4882/4885 |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR1 1/4885ALDH1A1 3300/4885TP53 4649/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR1 2/4885ALDH1A1 4229/4885TP53 4396/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR1 2/4885ALDH1A1 2284/4885TP53 4769/4885 |
| US-20060058293-A1 | Combination of bupropion and a second compound for affecting weight loss | MC4R, MC3R, MC5R | CNR1 24/4885ALDH1A1 4366/4885TP53 4854/4885 |
| US-20040254208-A1 | Using mixture of opioid receptor antagonist and melanocortin antagonist; suppression appetites | MC4R, MC3R, MC5R | CNR1 82/4885ALDH1A1 4405/4885TP53 4834/4885 |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885ALDH1A1 3600/4885TP53 4814/4885 |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885ALDH1A1 3600/4885TP53 4814/4885 |
| US-20230404990-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CNR1, CNR2, CHRNA2 | CNR1 1/4885ALDH1A1 3740/4885TP53 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.